
{
  "Company Overview": {
    "Name": "Hester Biosciences Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Formulations",
    "Business Description": "One of the leading animal health care companies & the second largest poultry vaccine manufacturer in India.  Operates across four verticals: Poultry Vaccines, Poultry Health Products, Animal Vaccines, and Animal Health Products. Provides services like seroprofiling kits and diagnostic labs for poultry flocks, and mastitis control programs for cattle.  Has a presence in over 30 countries, with key markets in India, Nepal & Tanzania. Partnered with Bill & Melinda Gates Foundation, GALVmed, Golchha Organisation, Novapharma, etc.",
    "Market Position": "World’s largest manufacturer and supplier of PPR vaccines (~75% market share). 70%+ market share in Goat Pox vaccine in India. Second largest poultry vaccine manufacturer in India (~35% market share)."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 2,018 Cr.",
    "Current Price": "₹ 2,372",
    "High/Low": "₹ 3,379 / ₹ 1,293",
    "P/E Ratio": 86.0,
    "Book Value": "₹ 355",
    "Dividend Yield": "0.25%",
    "ROCE": "9.32%",
    "ROE": "6.60%",
    "Face Value": "₹ 10.0"
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [62.66, 55.69, 56.47, 50.70, 73.15, 74.94, 67.30, 87.85, 70.46, 66.98, 79.26, 82.27, 83.69], 
      "Expenses": [45.10, 40.66, 46.15, 43.27, 60.40, 56.18, 55.63, 73.49, 57.24, 56.83, 63.34, 64.62, 64.53],
      "Operating Profit": [17.56, 15.03, 10.32, 7.43, 12.75, 18.76, 11.67, 14.36, 13.22, 10.15, 15.92, 17.65, 19.16],
      "OPM %": ["28.02%", "26.99%", "18.28%", "14.65%", "17.43%", "25.03%", "17.34%", "16.35%", "18.76%", "15.15%", "20.09%", "21.45%", "22.89%"],
      "Other Income": [1.42, 2.78, 7.62, 4.69, 5.01, 6.37, 3.49, 2.52, 5.91, 2.20, 4.63, 2.09, 2.80],
      "Interest": [0.74, 0.96, 1.50, 1.60, 2.46, 3.89, 1.37, 2.57, 8.08, 2.19, 6.94, 5.01, 5.89],
      "Depreciation": [3.05, 5.17, 5.13, 5.06, 5.03, 5.24, 5.37, 5.40, 4.28, 3.75, 3.74, 4.13, 4.20],
      "Profit before tax": [15.19, 11.68, 11.31, 5.46, 10.27, 16.00, 8.42, 8.91, 6.77, 6.41, 9.87, 10.60, 11.87],
      "Tax %": ["26.73%", "28.68%", "20.34%", "34.98%", "35.74%", "24.00%", "32.19%", "24.69%", "40.18%", "37.44%", "35.16%", "29.34%", "29.32%"],
      "Net Profit": [11.13, 8.33, 9.00, 3.56, 6.60, 12.16, 5.71, 6.71, 4.04, 4.02, 6.40, 7.49, 8.39],
      "EPS in Rs": [12.48, 9.97, 9.07, 4.67, 8.16, 13.15, 5.33, 6.90, 4.81, 4.68, 5.82, 7.45, 9.64]
    },
    "Annual Results": {
      "Sales": [65, 69, 90, 101, 123, 136, 178, 183, 214, 235, 266, 305, 312],
      "Expenses": [43, 44, 64, 67, 82, 89, 110, 128, 146, 175, 215, 251, 249],
      "Operating Profit": [22, 24, 25, 34, 41, 47, 68, 55, 69, 60, 51, 54, 63],
      "OPM %": ["34%", "36%", "28%", "34%", "33%", "35%", "38%", "30%", "32%", "26%", "19%", "18%", "20%"],
      "Other Income": [0, 1, 3, 1, 0, 3, 7, 6, 1, 14, 20, 15, 12],
      "Interest": [3, 6, 5, 4, 4, 4, 7, 7, 7, 4, 9, 20, 20],
      "Depreciation": [4, 5, 6, 6, 7, 10, 12, 13, 13, 17, 21, 17, 16],
      "Profit before tax": [14, 13, 18, 25, 31, 36, 57, 41, 50, 54, 40, 32, 39],
      "Tax %": ["37%", "31%", "26%", "23%", "26%", "36%", "28%", "25%", "31%", "26%", "30%", "34%", "37%"],
      "Net Profit": [9, 9, 13, 19, 23, 23, 41, 31, 35, 39, 28, 21, 26],
      "EPS in Rs": [10.89, 11.11, 15.99, 22.57, 27.68, 30.12, 48.87, 34.29, 40.47, 46.22, 31.30, 22.21, 27.59]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "16%",
      "Compounded Sales Growth (5 Years)": "11%",
      "Compounded Sales Growth (3 Years)": "12%",
      "Compounded Sales Growth (TTM)": "4%",
      "Compounded Profit Growth (10 Years)": "8%",
      "Compounded Profit Growth (5 Years)": "-14%",
      "Compounded Profit Growth (3 Years)": "-20%",
      "Compounded Profit Growth (TTM)": "-8%",
      "Stock Price CAGR (10 Years)": "22%",
      "Stock Price CAGR (5 Years)": "10%",
      "Stock Price CAGR (3 Years)": "-2%",
      "Stock Price CAGR (1 Year)": "62%"
    },
    "Liquidity Ratios": {
      "Debtor Days": [85, 75, 72, 95, 79, 87, 67, 116, 84, 86, 109, 94],
      "Inventory Days": [736, 1145, 431, 627, 376, 505, 540, 834, 452, 424, 399, 288],
      "Days Payable": [135, 145, 68, 109, 84, 100, 93, 261, 204, 101, 141, 101],
      "Cash Conversion Cycle": [685, 1074, 434, 614, 371, 491, 514, 690, 332, 409, 367, 281],
      "Working Capital Days": [137, 194, 158, 188, 145, 150, 153, 169, 172, 204, 203, 181]
    },
    "Profitability Ratios": {
      "ROCE %": [20, 18, 15, 19, 19, 20, 26, 16, 18, 14, 9, 9],
      "Return on Equity (10 Years)": "15%",
      "Return on Equity (5 Years)": "12%",
      "Return on Equity (3 Years)": "11%",
      "Return on Equity (Last Year)": "7%"
    },
    "Valuation Ratios": {
      "Price to Book": null, 
      "Market Cap / Sales": null,
      "EV / EBITDA": null
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Torrent Pharma.", "CMP": 3437.00, "P/E": 66.84, "Mar Cap": 116318.47, "Div Yld": 0.81, "NP Qtr": 453.00, "Qtr Profit Var": 17.36, "Sales Qtr": 2889.00, "Qtr Sales Var": 8.61, "ROCE": 23.16},
      {"Name": "Ajanta Pharma", "CMP": 2866.45, "P/E": 40.92, "Mar Cap": 35805.43, "Div Yld": 1.26, "NP Qtr": 216.48, "Qtr Profit Var": 10.84, "Sales Qtr": 1186.64, "Qtr Sales Var": 15.38, "ROCE": 31.60},
      {"Name": "Gland Pharma", "CMP": 1772.30, "P/E": 42.22, "Mar Cap": 29198.95, "Div Yld": 1.13, "NP Qtr": 163.53, "Qtr Profit Var": -15.74, "Sales Qtr": 1405.83, "Qtr Sales Var": 2.36, "ROCE": 13.58},
      {"Name": "ERIS Lifescience", "CMP": 1380.30, "P/E": 54.12, "Mar Cap": 18789.92, "Div Yld": 0.00, "NP Qtr": 96.35, "Qtr Profit Var": -25.12, "Sales Qtr": 741.17, "Qtr Sales Var": 46.68, "ROCE": 11.27},
      {"Name": "Caplin Point Lab", "CMP": 2311.45, "P/E": 35.62, "Mar Cap": 17569.72, "Div Yld": 0.22, "NP Qtr": 130.81, "Qtr Profit Var": 13.87, "Sales Qtr": 483.10, "Qtr Sales Var": 17.81, "ROCE": 26.46},
      {"Name": "Sai Life", "CMP": 703.65, "P/E": 176.75, "Mar Cap": 14635.18, "Div Yld": 0.00, "NP Qtr": 28.01, "Qtr Profit Var": 675.29, "Sales Qtr": 5.13, "Qtr Sales Var": 10.57, "ROCE": 10.57},
      {"Name": "Marksans Pharma", "CMP": 304.90, "P/E": 39.92, "Mar Cap": 13816.96, "Div Yld": 0.20, "NP Qtr": 97.76, "Qtr Profit Var": 15.80, "Sales Qtr": 641.92, "Qtr Sales Var": 20.83, "ROCE": 20.61},
      {"Name": "Hester Bios", "CMP": 2371.65, "P/E": 85.96, "Mar Cap": 2017.53, "Div Yld": 0.25, "NP Qtr": 8.39, "Qtr Profit Var": 102.97, "Sales Qtr": 83.69, "Qtr Sales Var": 18.78, "ROCE": 9.32}
    ],
    "Median": {
      "CMP": 372.42,
      "P/E": 36.33,
      "Mar Cap": 520.58,
      "Div Yld": 0.14,
      "NP Qtr": 7.85,
      "Qtr Profit Var": 10.84,
      "Sales Qtr": 69.66,
      "Qtr Sales Var": 10.68,
      "ROCE": 13.41
    }
  },
  "Other Insights": {
    "Pros": "Company has been maintaining a healthy dividend payout of 24.8%",
    "Cons": [
      "Stock is trading at 6.68 times its book value",
      "The company has delivered a poor sales growth of 11.3% over past five years.",
      "Company has a low return on equity of 10.6% over last 3 years."
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis." ,
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Documents": {
    "Announcements": [
      {"Date": "1d", "Title": "CARE Ratings reaffirms credit ratings for Hester Biosciences."},
      {"Date": "12 Nov", "Title": "Appointment of new CFO and KMP changes."},
      {"Date": "12 Nov", "Title": "Appointment of Mr. Divyesh Maru as CFO."},
      {"Date": "12 Nov", "Title": "Appointment of Mr. Divyesh Maru as CFO."},
      {"Date": "30 Oct", "Title": "Transcripts of Q2 FY25 earnings conference call."}
    ],
    "Annual Reports": [
      {"Year": 2024, "Source": "bse"},
      {"Year": 2023, "Source": "bse"},
      {"Year": 2022, "Source": "bse"},
      {"Year": 2021, "Source": "bse"},
      {"Year": 2020, "Source": "bse"},
      {"Year": 2019, "Source": "bse"},
      {"Year": 2018, "Source": "bse"},
      {"Year": 2017, "Source": "bse"},
      {"Year": 2016, "Source": "bse"},
      {"Year": 2015, "Source": "bse"},
      {"Year": 2014, "Source": "bse"},
      {"Year": 2013, "Source": "bse"},
      {"Year": 2012, "Source": "bse"},
      {"Year": 2011, "Source": "bse"},
      {"Year": 2010, "Source": "bse"}
    ],
    "Credit Ratings": [
      {"Date": "5 Jan", "Source": "care"},
      {"Date": "7 Jul 2023", "Source": "care"},
      {"Date": "7 Feb 2023", "Source": "care"},
      {"Date": "21 Jan 2022", "Source": "care"},
      {"Date": "11 Nov 2020", "Source": "care"},
      {"Date": "11 Nov 2020", "Source": "care"}
    ],
    "Concalls": { /*Extensive list of concall details omitted for brevity*/ }
  }
}
